338 results on '"Stingl, Julia C."'
Search Results
2. Metabolic activation of WHO-congeners PCB28, 52, and 101 by human CYP2A6: evidence from in vitro and in vivo experiments
3. Dealing with adverse drug reactions in the context of polypharmacy using regression models
4. Clinical Applications of Pharmacogenetics in Improving Drug Safety
5. Association of Polymorphic Cytochrome P450 Enzyme Pathways with Falls in Multimedicated Older Adults
6. Use of overactive bladder anticholinergic medications associated with falls leading to emergency department visits: results from the ADRED study
7. Inhalation therapies in COPD — adverse drug reactions impact on emergency department presentations
8. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
9. Pharmacokinetic interaction of quetiapine and lamotrigine – victim and perpetrator?
10. Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes.
11. Fall-Associated Drugs in Community-Dwelling Older Adults: Results from the ActiFE Ulm Study
12. Hypoglycemia in Older Adults: Time Trends and Treatment Differences in Patients Aged ≥75 Years With Type 2 Diabetes
13. Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis
14. Targeting Cholesterol Metabolism as Efficient Antiviral Strategy Against the Hepatitis E Virus
15. Guía de consenso de expertos para la monitorización terapéutica de drogas en neuropsicofarmacología
16. Pregnancy exposure to venlafaxine—Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes
17. Assessment of Substrate Status of Drugs Metabolized by Polymorphic Cytochrome P450 (CYP) 2 Enzymes: An Analysis of a Large-Scale Dataset
18. Nutrimetric Validation of Solanidine as Dietary‐Derived CYP2D6 Activity Marker In Vivo
19. Genetic polymorphism of CYP2C19 and subcortical variability in the human adult brain
20. Personalising drug safety—results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED)
21. Over- and undertreatment with levothyroxine—findings of the population-based Rhineland Study
22. Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie: Zusammenfassung der Konsensusleitlinien 2017 der TDM-Arbeitsgruppe der AGNP
23. Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine
24. The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression
25. Prevalence and determinants of over- and undertreatment among users of antihypertensive drugs in the general population: the Rhineland Study
26. Pregnancy exposure to citalopram – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood
27. Multimodal FLAIR/MPRAGE segmentation of cerebral cortex and cortical myelin
28. Predicting CYP2D6 phenotype from resting brain perfusion images by gradient boosting
29. Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity
30. Adverse drug reactions in older adults: a retrospective comparative analysis of spontaneous reports to the German Federal Institute for Drugs and Medical Devices
31. Signals of anticipation of reward and of mean reward rates in the human brain
32. Nutrimetric Validation of Solanidine as Dietary‐Derived CYP2D6 Activity Marker In Vivo.
33. Erratum zu: Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie: Zusammenfassung der Konsensusleitlinien 2017 der TDM-Arbeitsgruppe der AGNP
34. A 12-gene pharmacogenetic panel to prevent adverse drug reactions : an open-label, multicentre, controlled, cluster-randomised crossover implementation study
35. Pharmacogenomics and Precision Psychiatry
36. The gradient model of brain organization in decisions involving “empathy for pain”
37. Inhalation therapies in COPD — adverse drug reactions impact on emergency department presentations
38. Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant ‐ implications for precision dosing in a global perspective
39. Emergency Department Visits Due to Dyspnea: Association with Inhalation Therapy in COPD and Cases with Adverse Drug Reactions
40. Emergency Department Visits Due to Dyspnea: Association with Inhalation Therapy in COPD and Cases with Adverse Drug Reactions
41. The gradient model of brain organization in decisions involving "empathy for pain".
42. Effect of paroxetine and bupropion on human resting brain perfusion: An arterial spin labeling study
43. Prevalence and comorbidity of chronic pain in the German general population
44. Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans
45. Green Tea Extract to Prevent Colorectal Adenomas, Results of a Randomized, Placebo-Controlled Clinical Trial
46. Comparative Investigation of Methods for Analysis of SARS-CoV-2-Spike-Specific Antisera
47. Validation of self‐reported medication use applying untargeted mass spectrometry‐based metabolomics techniques in the Rhineland study
48. Clonal Hematopoiesis–Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer
49. Antidepressant drug treatment protecting from COVID-19: one more piece in the repurposing puzzle
50. Prevalence of ABCB1 3435C>T polymorphism in the Cuban population
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.